HUTCHMED (China) Limited (AIM:HCM)

Market Cap	1.99B
Revenue (ttm)	503.39M
Net Income (ttm)	30.14M
Shares Out	854.88M
EPS (ttm)	0.03
PE Ratio	72.93
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	21,038
Average Volume	46,620
Open	231.00
Previous Close	233.00
Day's Range	225.00 - 231.00
52-Week Range	206.00 - 353.00
Beta	0.75
RSI	43.88
Earnings Date	Mar 5, 2025

About HUTCHMED (China)

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, an...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2000
• Employees: 1,988
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: HCM

Financial Performance

In 2024, HUTCHMED (China)'s revenue was $630.20 million, a decrease of -24.80% compared to the previous year's $838.00 million. Earnings were $37.73 million, a decrease of -62.56%.

Financial numbers in USD